🟢 GT Biopharma is trading 6.48% up in pre-market after its 1-for-25 reverse stock split took effect

GT Biopharma is trading at $5.59 (+6.48%) in pre-market, having rebounded following its 1-for-25 reverse stock split, effective September 8, 2026.

• Nasdaq confirmed split-adjusted trading and a new CUSIP.
• Outstanding shares fell from approximately 45.1 million to 1.8 million.
• The move appears tied to post-split trading dynamics rather than newly reported overnight fundamentals; volume and activity-level data were unavailable.